Author

Katherine L. Morel

The University of AdelaideORCID 0000-0002-7968-4032Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Beatriz GermaniD· 2 shared Deborah L. BurkhartiD· 2 shared Himisha BeltraniD· 2 shared Leigh EllisiD· 2 shared Matthew L. FreedmaniD· 2 shared Anjali V. SheahaniD· 1 shared Ayesha A. ShafiiD· 1 shared Christopher J. SweeneyiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Beatriz GermanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintAug 7, 2025

EZH2-TTP-mTORC1 Axis Drives Phenotypic Plasticity and Therapeutic Vulnerability in Lethal Prostate Cancer

Beatriz German, Katherine L. Morel, Teia Noel…·Leigh Ellis

This paper identifies the EZH2-TTP-mTORC1 axis as a driver of phenotypic plasticity and therapeutic vulnerability in prostate cancer, showing that combined inhibition of EZH2 and PI3K/mTORC1 improves anti-tumor activity.

1 citation

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologyCancer Research CommunicationsPeer-reviewedAug 8, 2024

MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer

Beatriz German, Sarah Abou Alaiwi, Kun-Lin Ho…·Leigh Ellis

This study identifies MYBL2 as a master regulator of phenotypic plasticity in prostate cancer and shows CDK2 inhibition as a potential therapeutic strategy for MYBL2-driven tumors.

19 citations

mousebulk RNA-seq

𝕏 PostBluesky